Coverart for item
The Resource Melanoma : molecular biology, risk factors and treatment options, Alexander C. Jones, editor

Melanoma : molecular biology, risk factors and treatment options, Alexander C. Jones, editor

Label
Melanoma : molecular biology, risk factors and treatment options
Title
Melanoma
Title remainder
molecular biology, risk factors and treatment options
Statement of responsibility
Alexander C. Jones, editor
Contributor
Subject
Language
eng
Summary
Melanoma accounts for only 4% of all skin cancer cases but most of skin cancer-related death. The rising incidence of melanoma makes this tumor an important public health problem. In this book, the authors present current research in the study of the molecular biology, risk factors and treatment options for melanoma. Topics include the role of P13K/AKT and Wnt/<U+00dd>-Catenin pathways in melanoma's progression to metastatic disease; cutaneous melanoma; molecular determinants of melanoma vasculogenic mimicry; new aspects of the molecular biology of melanoma metastasis; the surgical extent of regional
Member of
Cataloging source
N$T
Dewey number
616.99/477
Index
index present
LC call number
RC280.M37
LC item number
M45 2013eb
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
http://library.link/vocab/relatedWorkOrContributorName
Jones, Alexander C
Series statement
Cancer etiology, diagnosis, and treatments
http://library.link/vocab/subjectName
  • Melanoma
  • Melanoma
  • HEALTH & FITNESS
  • MEDICAL
  • MEDICAL
  • MEDICAL
  • MEDICAL
  • Melanoma
  • Melanoma
  • Melanoma
  • Melanoma
Label
Melanoma : molecular biology, risk factors and treatment options, Alexander C. Jones, editor
Instantiates
Publication
Antecedent source
unknown
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • ""MELANOMA: MOLECULAR BIOLOGY, RISK FACTORS AND TREATMENT OPTIONS""; ""MELANOMA: MOLECULAR BIOLOGY, RISK FACTORS AND TREATMENT OPTIONS""; ""Library of Congress Cataloging-in-Publication Data""; ""Contents""; ""Preface""; ""Chapter 1: Melanoma Progression to Metastatic Disease: The Role of the PI3K/AKT and Wnt/Î2-Catenin Pathways""; ""Abstract""; ""1. PI3K/AKT Signaling Pathway and Its Components""; ""1.1. Overview""; ""1.2. Components of the PI3K Pathway""; ""1.2.1. PI3K Isoforms""; ""1.2.2. Phosphatase and Tensin Homologue Deleted on Chromosome 10 (PTEN)""; ""1.2.3. AKT""
  • ""1.3. PI3K Pathway Activation and Downstream Targets""""1.4. PI3K in Cancer""; ""2. PI3K Pathway in Melanoma""; ""2.1. Melanoma""; ""2.1.1. Overview""; ""2.1.2. Stages of Melanoma""; ""2.1.3. Melanoma and Common Mutations of Signaling Pathways""; ""2.2. PI3K and Melanoma Progression""; ""3. PI3K Mediated Crosstalk in Melanoma Progression""; ""3.1. PI3K â€? MAPK Crosstalk""; ""ERK 1/2 Module""; ""JNK Module""; ""3.2. PI3K â€? NF-Î&#x00BA;B Cross Talk""; ""3.3. PI3K â€? TGFÎ2 Pathway Crosstalk""; ""3.4. PI3K â€? Notch Pathway Crosstalk""; ""3.5. PI3K â€? JAK-STAT Pathway Crosstalk""
  • ""3.6. PI3K- mTOR Crosstalk""""4. Wnt/Î2-Catenin and PI3K Pathway""; ""4.1. Î2-Catenin""; ""4.1.1. Structure and Function""; ""At Cellular Membrane""; ""In the Cytoplasm and Nucleus""; ""4.1.2. Î2-Catenin/Canonical Wnt Pathway""; ""4.1.3. Active Î2-Catenin""; ""4.1.4. Localization""; ""4.1.5. Î2-Catenin in Cancer""; ""4.1.6. Î2-Catenin in Melanoma""; ""4.2. Crosstalk between the PI3K and Canonical Wnt Pathways in Melanoma Progression""; ""4.2.1. GSK3Î2 As a Potential Candidate to Mediate Crosstalk between Wnt/Î2-Catenin and PI3K Pathways""
  • ""4.2.2. Other Potential Candidates That Mediate Crosstalk between Wnt/Î2-Catenin and PI3K Pathways""""4.2.2.1. AKT""; ""4.2.2.2. PI3K""; ""4.2.2.3. mTOR""; ""4.2.2.4. TGFÎ21""; ""Current Therapeutics of Melanoma and Concluding Remarks""; ""References""; ""Chapter 2: Cutaneous Melanoma: Molecular Biology, Risk Factors and Treatment Options""; ""Abstract""; ""1. The Biology of Cutaneous Melanoma""; ""1.1. Risk Factors""; ""1.2. Development of Cutaneous Melanoma""; ""1.2.1. Models for heterogeneity in Cutaneous Melanoma""
  • ""1.2.2. Pathways Involved in Cutaneous Melanoma Development and Progression""""Cell Proliferation and Angiogenesis Pathways""; ""Pigment Synthesis Pathways""; ""1.3. Cutaneous Melanoma and the Immune System""; ""The theory of Cancer Immunoediting""; ""Evidences of immunoediting in Cutaneous Melanoma""; ""2. Cutaneous Melanoma Treatment and Management""; ""2.1. Targeted Therapies""; ""2.2. Immunotherapy""; ""2.2.1. Therapeutic Vaccines""; ""2.2.2. Our Experience with Therapeutic Vaccines""; ""Therapeutic Vaccines of Irradiated Allogeneic Cutaneous Melanoma Cells""
Control code
857233286
Dimensions
unknown
Extent
1 online resource (xiii, 239 pages)
File format
unknown
Form of item
online
Isbn
9781628086119
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
(OCoLC)857233286
Label
Melanoma : molecular biology, risk factors and treatment options, Alexander C. Jones, editor
Publication
Antecedent source
unknown
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • ""MELANOMA: MOLECULAR BIOLOGY, RISK FACTORS AND TREATMENT OPTIONS""; ""MELANOMA: MOLECULAR BIOLOGY, RISK FACTORS AND TREATMENT OPTIONS""; ""Library of Congress Cataloging-in-Publication Data""; ""Contents""; ""Preface""; ""Chapter 1: Melanoma Progression to Metastatic Disease: The Role of the PI3K/AKT and Wnt/Î2-Catenin Pathways""; ""Abstract""; ""1. PI3K/AKT Signaling Pathway and Its Components""; ""1.1. Overview""; ""1.2. Components of the PI3K Pathway""; ""1.2.1. PI3K Isoforms""; ""1.2.2. Phosphatase and Tensin Homologue Deleted on Chromosome 10 (PTEN)""; ""1.2.3. AKT""
  • ""1.3. PI3K Pathway Activation and Downstream Targets""""1.4. PI3K in Cancer""; ""2. PI3K Pathway in Melanoma""; ""2.1. Melanoma""; ""2.1.1. Overview""; ""2.1.2. Stages of Melanoma""; ""2.1.3. Melanoma and Common Mutations of Signaling Pathways""; ""2.2. PI3K and Melanoma Progression""; ""3. PI3K Mediated Crosstalk in Melanoma Progression""; ""3.1. PI3K â€? MAPK Crosstalk""; ""ERK 1/2 Module""; ""JNK Module""; ""3.2. PI3K â€? NF-Î&#x00BA;B Cross Talk""; ""3.3. PI3K â€? TGFÎ2 Pathway Crosstalk""; ""3.4. PI3K â€? Notch Pathway Crosstalk""; ""3.5. PI3K â€? JAK-STAT Pathway Crosstalk""
  • ""3.6. PI3K- mTOR Crosstalk""""4. Wnt/Î2-Catenin and PI3K Pathway""; ""4.1. Î2-Catenin""; ""4.1.1. Structure and Function""; ""At Cellular Membrane""; ""In the Cytoplasm and Nucleus""; ""4.1.2. Î2-Catenin/Canonical Wnt Pathway""; ""4.1.3. Active Î2-Catenin""; ""4.1.4. Localization""; ""4.1.5. Î2-Catenin in Cancer""; ""4.1.6. Î2-Catenin in Melanoma""; ""4.2. Crosstalk between the PI3K and Canonical Wnt Pathways in Melanoma Progression""; ""4.2.1. GSK3Î2 As a Potential Candidate to Mediate Crosstalk between Wnt/Î2-Catenin and PI3K Pathways""
  • ""4.2.2. Other Potential Candidates That Mediate Crosstalk between Wnt/Î2-Catenin and PI3K Pathways""""4.2.2.1. AKT""; ""4.2.2.2. PI3K""; ""4.2.2.3. mTOR""; ""4.2.2.4. TGFÎ21""; ""Current Therapeutics of Melanoma and Concluding Remarks""; ""References""; ""Chapter 2: Cutaneous Melanoma: Molecular Biology, Risk Factors and Treatment Options""; ""Abstract""; ""1. The Biology of Cutaneous Melanoma""; ""1.1. Risk Factors""; ""1.2. Development of Cutaneous Melanoma""; ""1.2.1. Models for heterogeneity in Cutaneous Melanoma""
  • ""1.2.2. Pathways Involved in Cutaneous Melanoma Development and Progression""""Cell Proliferation and Angiogenesis Pathways""; ""Pigment Synthesis Pathways""; ""1.3. Cutaneous Melanoma and the Immune System""; ""The theory of Cancer Immunoediting""; ""Evidences of immunoediting in Cutaneous Melanoma""; ""2. Cutaneous Melanoma Treatment and Management""; ""2.1. Targeted Therapies""; ""2.2. Immunotherapy""; ""2.2.1. Therapeutic Vaccines""; ""2.2.2. Our Experience with Therapeutic Vaccines""; ""Therapeutic Vaccines of Irradiated Allogeneic Cutaneous Melanoma Cells""
Control code
857233286
Dimensions
unknown
Extent
1 online resource (xiii, 239 pages)
File format
unknown
Form of item
online
Isbn
9781628086119
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
(OCoLC)857233286

Library Locations

    • Thomas Jefferson LibraryBorrow it
      1 University Blvd, St. Louis, MO, 63121, US
      38.710138 -90.311107
Processing Feedback ...